Marker Therapeutics Inc (MRKR)

A. Company Overview

Marker Therapeutics Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of innovative T cell-based immunotherapies specifically targeting hematological malignancies and solid tumors. The company is at the forefront of utilizing a proprietary technology termed multi tumor-associated antigen (multiTAA)-specific T cell therapy, which enables the manufacture of non-engineered, tumor-specific T cells capable of recognizing multiple tumor-associated antigens (TAAs). This approach is designed to expand tumor-targeted T cells harvested from a patient's or donor's blood, utilizing the natural capacity of T cells to detect and eradicate cancer cells.

Technology and Approach

The multiTAA-specific T cell technology is built around the concept of creating T cells that can target several antigens simultaneously. By harnessing the body's intrinsic immune mechanisms, this method aims to generate a robust anti-tumor response while minimizing opportunities for tumors to adapt or escape treatment through antigen loss. This strategy is positioned as potentially more effective than genetically engineered T cell therapies, such as CAR-T cells, that are limited by their focus on single antigens.

Marker Therapeutics licensed the technology from Baylor College of Medicine (BCM) in March 2018, where it was previously employed in exploratory clinical trials that demonstrated encouraging results in treating various cancers, including lymphoma, multiple myeloma, and acute leukemias.

Product Pipeline and Clinical Trials

Marker Therapeutics is developing two primary product candidates, MT-601 and MT-401, which are advancing through clinical trials for specific cancer types:

MT-601

Indications: For treating relapsed or refractory lymphoma and pancreatic cancer.

• Lymphoma: MT-601 is an autologous T cell product that targets six specific tumor antigens commonly overexpressed in lymphoma (e.g., Survivin, PRAME). The Phase 1 study, named APOLLO, aims to evaluate the safety and efficacy of MT-601 in patients who have either failed or are ineligible for anti-CD19 CAR T cell therapies. Early results have been promising, indicating tolerability and a complete metabolic response in some participants shortly after treatment.
• Pancreatic Cancer: MT-601 is also being assessed in a Phase 1/2 clinical trial for advanced pancreatic adenocarcinoma (TACTOPS), with interim results revealing that 31% of patients exhibited objective responses correlating with the presence of tumor-reactive T cells post-treatment.

MT-401 and MT-401-OTS Program

Indications: Targeted at acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

• The MT-401 program includes a previously conducted Phase 2 study (ARTEMIS), now discontinued in favor of developing a more scalable off-the-shelf product (MT-401-OTS). This initiative aims to provide rapid treatment options for patients with AML, potentially leveraging an "off-the-shelf" access model from a cellular inventory drawn from healthy donors. The projected first dosing for a patient in the MT-401-OTS program is anticipated in the second half of 2024.

Manufacturing and Process Development

Marker Therapeutics employs a high-efficiency manufacturing process optimized to produce multiTAA-specific T cells, achieving a reduction in production time from 36 days to just nine days. Central to the manufacturing are G-Rex devices that support large-scale T cell expansion in a controlled environment that enhances oxygen and nutrient availability. This innovative approach enables the identification, activation, and expansion of the desired T cell populations while ensuring high product quality and potency.

The manufacturing capabilities are underpinned by strategic partnerships, including a recent contract with Cell Ready for development and manufacturing support, enhancing operational efficiency and scalability.

Strategic Partnerships and Collaborations

Marker Therapeutics maintains collaborative relationships with BCM and various scientific advisors. These alliances provide critical insights and resources that bolster its clinical development framework and regulatory pathways. Such relationships are vital for continuing efforts in exploring novel therapy combinations and expanding potential treatment applications.

Regulatory Landscape

The FDA and international regulatory bodies heavily regulate the clinical development process for Marker’s product candidates, which must undergo extensive preclinical and clinical trials before commercialization. The company has pursued regulatory designations like orphan drug status aimed at expediting the development of MT-601 for pancreatic cancer, given the pressing need for effective treatments in this area.

Intellectual Property

Marker Therapeutics' advancements rely significantly on intellectual property protections derived from its licensing agreements and proprietary technologies. The key components of its intellectual property portfolio include patents relating to the generation of multi-antigen specific T cell products and their therapeutic applications. Through its licensing agreement with BCM, Marker secures exclusive rights while committing to milestone payments and royalties linked to the commercialization of its product candidates.

Market Position and Competitive Landscape

Marker Therapeutics operates within a highly competitive immuno-oncology landscape, facing both established companies and emerging biotech firms. Its multiTAA-specific T cell approach distinguishes it as the only natural T cell product targeting multiple tumor antigens specifically designed for patients relapsing after treatment with existing CAR-T therapies. Market competitors include those advancing next-generation cellular therapies, including CAR and TCR-engineered products, as well as bispecific antibodies and other innovative platforms.

Future Aspirations

Marker Therapeutics aims to solidify its role as a leader in the immuno-oncology space by advancing its clinical candidates through rigorous trial phases, securing necessary regulatory approvals, and ultimately delivering transformative therapies that meet unmet patient needs across various cancer indications. The company’s strategic expansion plans could potentially diversify its therapeutic offerings and enhance patient access to advanced immunotherapy products as they emerge from clinical development.